Start-up Biotech dedicated to improving lives by delivering new medicines that stop #inflammation by inhibiting #NLRP3 inflammasome
Location: Ireland, Dublin City, Dublin
Employees: 11-50
Total raised: $126.82M
Founded date: 2016
Investors 3
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | Longitude ... | longitudec... |
| - | Fountain H... | fh-partner... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 25.03.2019 | - | $1M | - |
| 04.12.2018 | - | $63M | - |
| 19.11.2018 | Series B | $45.82M | - |
| 13.09.2016 | Series A | $17M | Fountain H... |
Mentions in press and media 15
| Date | Title | Description | Source |
| 23.09.2020 | Healthcare VC Firm Longitude Capital Closes $585M Fund | What You Should Know: – Healthcare venture capital firm Longitude Capital announces the close of it... | hitconsult... |
| 23.09.2020 | Longitude Capital Raises $585 Million Fund to Invest in Tran... | - Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, en... | marketscre... |
| 25.03.2019 | Inflazome Raises Over US$1M in Funding | Inflazome, a Dublin, Ireland- and Cambridge, UK-based biotech company developing several small molec... | finsmes.co... |
| 25.03.2019 | Inflazome receives funding from The Michael J. Fox Foundatio... | Inflazome receives funding from The Michael J. Fox Foundation for Parkinson’s research 25-03-2019 ... | cambridgen... |
| 25.03.2019 | Inflazome receives funding from The Michael J. Fox Foundatio... | Inflazome, the pioneering biotech company developing several small molecule drugs that inhibit harmf... | cambridgen... |
| 25.03.2019 | J&J, Bayer agree to $775M payout to settle Xarelto l... | → Right on deadline this morning we learned that J&J and Bayer have reached a deal to settle... | endpts.com... |
| 04.12.2018 | Queensland biotech startup Inflazome raises $63 million to c... | Inflazome chief executive Matt Cooper. Source: Supplied. Biotech startup Inflazome has raised $63 m... | smartcompa... |
| 19.11.2018 | Inflazome Raises €40M in Funding | Inflazome, a Dublin, Ireland-based developer of small molecule drugs that block harmful inflammation... | finsmes.co... |
| 19.11.2018 | Inflazome raises €40M to get NLRP3 drug into humans | Inflazome has raised €40 million ($46 million). The Forbion-led series B tees up Inflazome to trial ... | fiercebiot... |
| 19.11.2018 | Forbion Leads €40m Series B Financing in Inflazome to Develo... | Forbion, a leading European life science venture capital firm, today announces that it has led a Ser... | forbion.co... |
Show more